𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹. 𝗔𝗜. 𝗠𝗲𝗱𝗶𝗰𝗮𝗹 𝗔𝗳𝗳𝗮𝗶𝗿𝘀. 𝗦𝗮𝗳𝗲𝘁𝘆. 𝗤𝘂𝗮𝗹𝗶𝘁𝘆. 𝗪𝗵𝗲𝗿𝗲 𝗲𝗹𝘀𝗲 𝗱𝗼 𝗮𝗹𝗹 𝗼𝗳 𝘁𝗵𝗲𝘀𝗲 𝘄𝗼𝗿𝗹𝗱𝘀 𝗰𝗼𝗹𝗹𝗶𝗱𝗲? 🔬 Tamei Elliott, our Director of Global Scientific Content, says it best. #DIA2026 (June 14–18 | Philadelphia) is where the entire life sciences ecosystem comes together. Don't just dive deeper into your area, discover what's happening across all of them. 𝗚𝗲𝘁 𝘆𝗼𝘂𝗿 𝗽𝗮𝘀𝘀 👉 https://lnkd.in/esTFZ2-Q
DIA
Pharmaceutical Manufacturing
Washington, DC 50,173 followers
Driving collaboration in drug, device, and diagnostics development in pursuit of a healthier world
About us
DIA is the leading global life science membership association driving collaboration in drug, device, and diagnostics development in pursuit of a healthier world. Founded in 1964 with headquarters in Washington, D.C., and offices in Europe and Asia, DIA provides unparalleled networking opportunities, educational resources, scientific research publications, and professional development programs to members in more than 80 countries.
- Website
-
http://www.DIAglobal.org
External link for DIA
- Industry
- Pharmaceutical Manufacturing
- Company size
- 51-200 employees
- Headquarters
- Washington, DC
- Type
- Nonprofit
- Founded
- 1964
- Specialties
- Professional Association, Pharmaceuticals, Medical Devices, Biotechnology, Education Provider, Government, Clinical Trials, Education, Training, eLearning, Translational Medicine, Patient Engagement, Value and Access, healthcare, regulatory affairs, Pharmaco Vigilance, personaldevelopment, careers, women in science, and medicine
Locations
Employees at DIA
Updates
-
If you've been meaning to book your hotel for #DIA2026, today's the day. The discounted hotel block ends after today. Secure your stay near the venue and skip the scramble closer to the conference. 📍 Philadelphia, PA | June 14–18 🏙️ Book now → https://lnkd.in/eeb-isJn
-
-
⏰ Last chance: Deadline is TOMORROW! You still have until 22 May to submit your abstract and speak at two of DIA EMEAI's most anticipated conferences: ◾ 20th Medical Information & Communications Conference, London, 27–28 October ◾ 20th Global QPPV Forum, Amsterdam, 18–19 November 2026 Case study, lesson learned, or practical experience - your peers want to hear from you! #DIA #DIAQPPVForum2026 #DIAMedInfo2026 #Abstracts #CFA
📢 The deadline has been extended! This is your chance to speak at two of DIA EMEAI's most anticipated conferences - and you have until 22 May to submit your abstract. Whether it's a case study, a lesson learned, or a practical experience, your voice matters. Share it with a room full of peers who face the same challenges you do every day. ◾ 20th Medical Information & Communications Conference, London, 27-28 October: https://bit.ly/3ObZlha. ◾ 20th Global QPPV Forum, Amsterdam, 18-19 November 2026: https://bit.ly/41Ev0uU. #DIA #DIAQPPVForum2026 #DIAMedInfo2026 #Abstracts #CFA
-
-
DIA reposted this
DIA Webinar on May 28th The New Standard for ROI: Using Predictive AI to Insure & De-Risk Biotech Investments We are proud to announce that GATC Health’s Chief Business Officer, V. Tyrone Lam, will moderate this essential industry conversation. He will be joined by a panel of thought leaders, including our own Mark Flather, SVP of Business Development and Strategy. Featured Panelists: Dave Pfeiffer – SVP, Head of ARCAS, Biotech Erica Horwitz – Managing Director, Healthcare, RBC Capital Markets Mark Flather – SVP, Business Development and Strategy, GATC Health Register Now: https://lnkd.in/giumkV7i
-
Some conferences give you a badge and a schedule. DIA's 𝗢𝗹𝗶𝗴𝗼𝗻𝘂𝗰𝗹𝗲𝗼𝘁𝗶𝗱𝗲-𝗕𝗮𝘀𝗲𝗱 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 gives you a reason to stay in the room. From morning breakfast to afternoon receptions, every break is built for connection, not just coffee. ☕ Whether you're swapping insights over lunch, joining a roundtable discussion, or catching up at the end of the day, you'll leave with more than notes. You'll leave with people. 📍 September 23–25 | Arlington, VA 🔗 𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗻𝗼𝘄 👉 https://lnkd.in/dWY_e-6A
-
-
𝗔𝗜 𝗶𝘀 𝘁𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺𝗶𝗻𝗴 𝗹𝗶𝗳𝗲 𝘀𝗰𝗶𝗲𝗻𝗰𝗲𝘀, 𝗯𝘂𝘁 𝗮𝗿𝗲 𝘆𝗼𝘂 𝗸𝗲𝗲𝗽𝗶𝗻𝗴 𝘂𝗽 𝘄𝗶𝘁𝗵 𝘁𝗵𝗲 𝗿𝗲𝗴𝘂𝗹𝗮𝘁𝗶𝗼𝗻𝘀 𝗮𝗻𝗱 𝗴𝗼𝘃𝗲𝗿𝗻𝗮𝗻𝗰𝗲 𝗳𝗿𝗮𝗺𝗲𝘄𝗼𝗿𝗸𝘀 𝘁𝗵𝗮𝘁 𝗰𝗼𝗺𝗲 𝘄𝗶𝘁𝗵 𝗶𝘁? On June 9 (virtual), DIA 2026 is offering a Short Course designed to give life sciences professionals a practical, comprehensive look at AI in action, from real-world use cases to the compliance and governance frameworks shaping how we responsibly implement it. Here's what you'll walk away with: ✅ A clear understanding of AI applications and use cases across drug development and commercialization ✅ Knowledge of key global regulatory frameworks governing AI and GenAI in life sciences ✅ Tools to build and maintain AI governance processes within your organization 𝗦𝗵𝗼𝗿𝘁 𝗖𝗼𝘂𝗿𝘀𝗲: 𝗔𝗜 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀, 𝗘𝘁𝗵𝗶𝗰𝘀, 𝗥𝗲𝗴𝘂𝗹𝗮𝘁𝗶𝗼𝗻𝘀, 𝗮𝗻𝗱 𝗚𝗼𝘃𝗲𝗿𝗻𝗮𝗻𝗰𝗲 𝗳𝗼𝗿 𝗟𝗶𝗳𝗲 𝗦𝗰𝗶𝗲𝗻𝗰𝗲𝘀 Register here 👉 https://lnkd.in/dRuazVVf 📅 June 9 | 1:00–4:00 PM ET | Virtual 🎓 CE credit available! Can't attend live? Registered attendees get access to the recording for 2 months post-course. Register for 2+ Short Courses at the same time and save $50 on your #DIA2026 purchase. Not sure this course is the right fit? Explore the full lineup of DIA 2026 Short Courses to find the topics most relevant to your work → https://lnkd.in/dxAEKEpB #LifeSciences #AIRegulation #ArtificialIntelligence #RegulatoryAffairs #DrugDevelopment #ContinuingEducation #ProfessionalDevelopment #AIGovernance
-
-
DIA reposted this
I’m looking forward to joining colleagues from across the global life sciences community at DIA 2026 Global Annual Meeting in Philadelphia this year. What I value most about this meeting is the depth of conversation. Regulators, industry leaders, academia, the leaders of tomorrow, emerging innovators, and investors all in the same room, focused on moving drug development forward. The conversations that happen here don't happen anywhere else. Join me and add your voice to the future of life sciences innovation. #DrugDevelopment #RegulatoryScience #Biotech #ClinicalResearch #DIA2026 More: https://lnkd.in/gzcXETUs
-
-
𝗪𝗵𝗮𝘁 𝗶𝗳 𝗔𝗜 𝗰𝗼𝘂𝗹𝗱 𝗽𝗿𝗲𝗱𝗶𝗰𝘁 𝘄𝗵𝗲𝘁𝗵𝗲𝗿 𝘆𝗼𝘂𝗿 𝗱𝗿𝘂𝗴 𝘄𝗶𝗹𝗹 𝘀𝘂𝗰𝗰𝗲𝗲𝗱, 𝗯𝗲𝗳𝗼𝗿𝗲 𝘆𝗼𝘂 𝘀𝗽𝗲𝗻𝗱 𝗮 𝗱𝗼𝗹𝗹𝗮𝗿 𝗼𝗻 𝘁𝗿𝗶𝗮𝗹𝘀? 🧬 Join DIA for a must-attend 𝗳𝗿𝗲𝗲 webinar hosted by GATC Health: 𝗧𝗵𝗲 𝗡𝗲𝘄 𝗦𝘁𝗮𝗻𝗱𝗮𝗿𝗱 𝗳𝗼𝗿 𝗥𝗢𝗜: 𝗨𝘀𝗶𝗻𝗴 𝗣𝗿𝗲𝗱𝗶𝗰𝘁𝗶𝘃𝗲 𝗔𝗜 𝘁𝗼 𝗜𝗻𝘀𝘂𝗿𝗲 & 𝗗𝗲-𝗥𝗶𝘀𝗸 𝗕𝗶𝗼𝘁𝗲𝗰𝗵 𝗜𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁𝘀, on May 28. For the first time, a non-dilutive, insurance-backed capital pathway, powered by GATC Health's Derisq™ AI Report and endorsed by Lloyd's of London, is available to biotech companies looking to advance clinical programs with less risk and less dilution. Hear from experts across investment banking, insurance, and biotech operations: Mark Flather- SVP Business Development at GATC Health, Dave Pfeiffer- SVP Head of ARCAS Bio-Tech at Acrisure Re, and Erica Horwitz- Managing Director Healthcare Investment Banking at RBC Capital Markets, moderated by V. Tyrone Lam - Chief Business Development Officer at GATC Health. 📅 𝗠𝗮𝘆 𝟮𝟴 | 𝟵:𝟬𝟬 𝗔𝗠 𝗣𝗦𝗧 🔗 𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗙𝗿𝗲𝗲→ https://lnkd.in/esTFZ2-Q #Biotech #ClinicalTrials #PredictiveAI #DrugDevelopment #LifeSciences #Biopharma
-
-
DIA reposted this
DIA is partnering with Innovation Network to bring a first-of-its-kind startup experience to DIA's 2026 Global Annual Meeting. DIA's Global Annual Meeting has long been the premier gathering where biopharma, regulators, academia, and patient advocates converge. It's where cross-functional teams connect, where global perspectives meet, and where the conversations that shape drug development happen. Now, we're embedding a dedicated startup experience — the DIA LIFT Series with Whale Tank Pitch Competition directly into that ecosystem. Why does this matter? Startups don't exist in a vacuum. The most transformative innovations in drug development happen at the intersection of bold ideas AND deep industry context. By partnering with Innovation Network, we're giving emerging companies access to exactly that: ✅ A stage within one of the most cross-functional, globally connected meetings in the industry ✅ Engagement with biopharma leaders, investors, and exited founders who are there to guide — not just evaluate ✅ Opportunities beyond competition: Rising Star/Thunder Talk pitches, Truth Booths, and more If you're a startup working at the frontier of drug development, or an industry leader who wants to help shape the next generation of companies — we want to see you at #DIA2026. #Biotech #Startups #DrugDevelopment #Innovation #Biopharma #DIA
“What would make a startup program worth it?” Whale Tank started with this simple question. And that's why we built Whale Tank to offer practical value at every step: meaningful feedback, top-tier connections, pitch opportunities, workshops, and access to the DIA Global Annual Meeting at a deeply discounted price. Here are a few of the ways we’re working to make it worth your time. We hope you’ll join us in Philadelphia at the DIA Global Annual Meeting. Wave 3 submissions closes May 26. https://lnkd.in/dCCfJAkH #innovation #biotech #clintech #startups Robert Tepper Ron DePinho MD Dan Snyder David Wellis, Ph.D. C. Palani Palaniappan Raju Kucherlapati Bill Illis Peter Schaeffer Jeff Lee James Wabby, MTOPRA Rachel Ovens, MBA Mindy Gruba, M.P.H. Ligia Kilinski (Cevasco) Sahirzeeshan (Sahir) Ali Mey Boukenna , M.D., Ph.D. Dylan Peay, PhD James Zanewicz, JD, LLM, RTTP Vivian (Mingyue) Li, Ph.D., MBA Cynthia Cai Mayank Bhandari, MD Jerry Wang Sandeep Pulim M.D. Amy Ripston Edye Edens Carie Pierce Katie T. Jeff Smith
-
-
-
-
-
+1
-
-
𝗧𝗼𝗱𝗮𝘆 𝗶𝘀 #𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹𝗧𝗿𝗶𝗮𝗹𝘀𝗗𝗮𝘆, 𝗮𝗻𝗱 𝘁𝗵𝗲 𝗳𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗵𝗮𝘀 𝗻𝗲𝘃𝗲𝗿 𝗹𝗼𝗼𝗸𝗲𝗱 𝗺𝗼𝗿𝗲 𝗽𝗿𝗼𝗺𝗶𝘀𝗶𝗻𝗴. 🌍 Last year at DIA 2025, Craig Lipset, Co-Chair of the Decentralized Trials & Research Alliance (DTRA) , shared what excites him most: accessible trial tools are lowering barriers to drug development, meaning more organizations can now sponsor trials, and more patients, especially those with rare and neglected diseases, gain access to potential treatments. "𝗠𝗼𝗿𝗲 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝗯𝗲𝗶𝗻𝗴 𝗮𝗯𝗹𝗲 𝘁𝗼 𝗺𝗼𝘃𝗲 𝘁𝗵𝗿𝗼𝘂𝗴𝗵 𝘁𝗵𝗲 𝗽𝗶𝗽𝗲𝗹𝗶𝗻𝗲 𝗮𝗻𝗱 𝗿𝗲𝗮𝗰𝗵 𝗱𝗶𝗳𝗳𝗲𝗿𝗲𝗻𝘁 𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝗽𝗼𝗽𝘂𝗹𝗮𝘁𝗶𝗼𝗻𝘀 𝗶𝗻 𝗻𝗲𝗲𝗱." That's the promise of modern clinical trials. And it's exactly the kind of conversation happening at #DIA2026, June 14–18 in Philadelphia. 🎫 𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗳𝗼𝗿 𝗼𝘂𝗿 𝗯𝗶𝗴𝗴𝗲𝘀𝘁 𝗺𝗲𝗲𝘁𝗶𝗻𝗴 𝗼𝗳 𝘁𝗵𝗲 𝘆𝗲𝗮𝗿, 𝗗𝗜𝗔 𝟮𝟬𝟮𝟲: https://lnkd.in/e_qnv9gU #ClinicalResearch #DrugDevelopment #RareDisease #PatientAccess